<DOC>
	<DOC>NCT01559090</DOC>
	<brief_summary>The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI-546 in Japanese SLE patients.</brief_summary>
	<brief_title>Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus erythematosus (SLE)</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Fulfils at least 4 of the 11 American College of Rheumatology (ACR) classification criteria for SLE. Weight greater than or equal to 40.0 kg. Diagnosis of pediatric or adult SLE with chronic disease activity requiring ongoing treatment or observation for â‰¥ 24 weeks prior to screening. Currently receiving stable dose of oral prednisone and/or antimalarials/immunosuppressives. Active moderate to severe SLE disease based on SLE disease activity score. Active severe or unstable neuropsychiatric SLE. Active severe SLEdriven renal disease or unstable renal disease. Clinically significant active infection including ongoing and chronic infections. Known history of a primary immunodeficiency or an underlying condition such as human immunodeficiency virus infection or splenectomy that predisposes the subject to infection. Confirmed positive tests for hepatitis B or positive test for hepatitis C.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Japan</keyword>
	<keyword>Phase2</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>SLE, MEDI-546</keyword>
</DOC>